European regulators have recommended extending TRYNGOLZA to adults with fasting triglycerides of at least 880 mg/dL. The decision follows two Phase 3 trials demonstrating substantial triglyceride reductions and 85% fewer adjudicated acute pancreatitis events in a pooled analysis.
Arrowhead’s plozasiran data ease dosing concerns in complex patients, but Phase 3 results will decide its broader triglyceride market role.
Arrowhead has regulatory momentum in rare lipid disease. The harder test is turning REDEMPLO approval into durable global uptake.
Plozasiran clears CHMP but the real test is reimbursement. Europe's HTA bodies will now decide whether clinical FCS diagnosis is enough.
Arrowhead Pharmaceuticals is advancing plozasiran fast, but can it overcome the Ionis patent dispute? Read the deeper legal and commercial analysis.
Arrowhead Pharmaceuticals’ plozasiran posted durable triglyceride reductions at ACC.26. Read what the long-term data could change next.